As­traZeneca beefs up cell ther­a­py tool kit with gene edit­ing deal

As­traZeneca is li­cens­ing Revvi­ty’s gene-edit­ing tech­nol­o­gy in a non-ex­clu­sive agree­ment for an undis­closed amount in or­der to cre­ate cell ther­a­pies for the treat­ment of can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER